肺癌扩散加权(DW)MRI:ADC 重测重复性研究
研究在4家机构、3个MRI厂商设备上,对23例患者的30个>2cm恶性肺病灶行两次自由呼吸DW-MRI,评估全肿瘤ADC的重测重复性及后处理平台可重复性;全肿瘤ADC均值1.14×10⁻³mm²/s,瘤内变异系数7.1%,>3cm病灶为3.9%,跨平台可重复性优良,作者认为可用于多中心试验。
要点
- 全肿瘤ADC重测变异系数7.1%(95%CI 5.7-9.6%),一致性界限-18.0%至21.9%。
- >3cm病灶重复性更好:变异系数3.9%(95%CI 2.9-5.9%),一致性界限-10.2%至11.4%。
- 个体疗效评估中ADC变化>21.9%才反映治疗相关变化。
核心结论
- 自由呼吸DW-MRI方案用于恶性肺肿瘤可获得满意的瘤内重复性,且对后处理软件变化稳健,作者认为可支持其用于多中心试验。
- 个体患者疗效评估时,ADC变化>21.9%才反映治疗相关变化。
研究设计与样本
- 研究纳入23例患者的30个>2cm恶性肺病灶,在4家机构、3个MRI厂商设备上分两次扫描,采用回波平面扩散加权MRI(b=100、500和800s/mm²)获取全肿瘤ADC。
- 将首次检查的全肿瘤感兴趣区复制到第二次检查图像,并从一种后处理平台复制到开源平台,以评估ADC重复性和跨平台可重复性。
关键影像表现/征象
- 全肿瘤ADC值范围为0.66-1.94×10⁻³mm²/s,均值1.14×10⁻³mm²/s。
诊断标准与关键数值
- 全肿瘤ADC瘤内变异系数7.1%(95%CI 5.7-9.6%),一致性界限-18.0%至21.9%。
- >3cm病灶瘤内变异系数3.9%(95%CI 2.9-5.9%),一致性界限-10.2%至11.4%;<3cm病灶变异性是>3cm病灶的2.46倍。
- 不同后处理平台间ADC可重复性优良:Pearson R²=0.99,变异系数2.8%(95%CI 2.3-3.4%),一致性界限-7.4%至8.0%。
临床应用与阅片要点
- 作者认为该自由呼吸DW-MRI方案可用于多中心试验。
- 个体患者疗效评估时,ADC变化>21.9%才反映治疗相关变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To determine the test-retest repeatability of Apparent Diffusion Coefficient (ADC) measurements across institutions and MRI vendors, plus investigate the effect of post-processing methodology on measurement precision.
METHODS: Thirty malignant lung lesions >2 cm in size (23 patients) were scanned on two occasions, using echo-planar-Diffusion-Weighted (DW)-MRI to derive whole-tumour ADC (b = 100, 500 and 800smm-2). Scanning was performed at 4 institutions (3 MRI vendors). Whole-tumour volumes-of-interest were copied from first visit onto second visit images and from one post-processing platform to an open-source platform, to assess ADC repeatability and cross-platform reproducibility.
RESULTS: Whole-tumour ADC values ranged from 0.66-1.94x10-3mm2s-1 (mean = 1.14). Within-patient coefficient-of-variation (wCV) was 7.1% (95% CI 5.7-9.6%), limits-of-agreement (LoA) -18.0 to 21.9%. Lesions >3 cm had improved repeatability: wCV 3.9% (95% CI 2.9-5.9%); and LoA -10.2 to 11.4%. Variability for lesions <3 cm was 2.46 times higher. ADC reproducibility across different post-processing platforms was excellent: Pearson's R2 = 0.99; CoV 2.8% (95% CI 2.3-3.4%); and LoA -7.4 to 8.0%.
CONCLUSION: A free-breathing DW-MRI protocol for imaging malignant lung tumours achieved satisfactory within-patient repeatability and was robust to changes in post-processing software, justifying its use in multi-centre trials. For response evaluation in individual patients, a change in ADC >21.9% will reflect treatment-related change.
KEY POINTS: • In lung cancer, free-breathing DWI-MRI produces acceptable images with evaluable ADC measurement. • ADC repeatability coefficient-of-variation is 7.1% for lung tumours >2 cm. • ADC repeatability coefficient-of-variation is 3.9% for lung tumours >3 cm. • ADC measurement precision is unaffected by the post-processing software used. • In multicentre trials, 22% increase in ADC indicates positive treatment response.
引用
- Weller A, Papoutsaki MV, Waterton JC, et al. Diffusion-weighted (DW) MRI in lung cancers: ADC test-retest repeatability. Eur Radiol. 2017. PMID: 28396997. doi:10.1007/s00330-017-4828-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。